The flavivirus protease as a target for drug discovery

Abstract

Many flaviviruses are significant human pathogens causing considerable disease burdens, including encephalitis and hemorrhagic fever, in the regions in which they are endemic. A paucity of treatments for flaviviral infections has driven interest in drug development targeting proteins essential to flavivirus replication, such as the viral protease. During viral replication, the flavivirus genome is translated as a single polyprotein precursor, which must be cleaved into individual proteins by a complex of the viral protease, NS3, and its cofactor, NS2B. Because this cleavage is an obligate step of the viral life-cycle, the flavivirus protease is an attractive target for antiviral drug development. In this review, we will survey recent drug development studies targeting the NS3 active site, as well as studies targeting an NS2B/NS3 interaction site determined from flavivirus protease crystal structures.

This is a preview of subscription content, access via your institution.

References

  1. Ackermann M, and Padmanabhan R. 2001. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J Biol Chem, 276: 39926–39937.

    CAS  PubMed  Google Scholar 

  2. Aleshin A, Shiryaev S, Strongin A, and Liddington R. 2007. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci., 16: 795–806.

    CAS  PubMed  Google Scholar 

  3. Aravapalli S, Lai H, Teramoto T, Alliston K R, Lushington G H, Ferguson E L, Padmanabhan R, and Groutas W C. 2012. Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold. Bioorg Med Chem, 20: 4140–4148.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Arias C F, Preugschat F, and Strauss J H. 1993. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology, 193: 888–899.

    CAS  PubMed  Google Scholar 

  5. Ashour J, Laurent-Rolle M, Shi P Y, and Garcia-Sastre A. 2009. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol, 83: 5408–5418.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Asnis D S, Conetta R, Waldman G, and Teixeira A A. 2001. The West Nile virus encephalitis outbreak in the United States (1999–2000): from Flushing, New York, to beyond its borders. Ann N Y Acad Sci, 951: 161–171.

    CAS  PubMed  Google Scholar 

  7. Asnis D S, Conetta R, Teixeira A A, Waldman G, and Sampson B A. 2000. The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience. Clin Infect Dis, 30: 413–418.

    CAS  PubMed  Google Scholar 

  8. Assenberg R, Mastrangelo E, Walter T S, Verma A, Milani M, Owens R J, Stuart D I, Grimes J M, and Mancini E J. 2009. Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication. J Virol, 83: 12895–12906.

    CAS  PubMed Central  PubMed  Google Scholar 

  9. Bazan J F, and Fletterick R J. 1989. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology, 171: 637–639.

    CAS  PubMed  Google Scholar 

  10. Best S M, Morris K L, Shannon J G, Robertson S J, Mitzel D N, Park G S, Boer E, Wolfinbarger J B, and Bloom M E. 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol., 79: 12828–12839.

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Bodenreider C, Beer D, Keller T H, Sonntag S, Wen D, Yap L, Yau Y H, Shochat S G, Huang D, Zhou T, Caflisch A, Su X C, Ozawa K, Otting G, Vasudevan S G, Lescar J, and Lim S P. 2009. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem, 395: 195–204.

    CAS  PubMed  Google Scholar 

  12. Bressanelli S, Stiasny K, Allison S L, Stura E A, Duquerroy S, Lescar J, Heinz F X, and Rey F A. 2004. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J., 23: 728–738.

    CAS  PubMed  Google Scholar 

  13. Brinton M A. 1981. Isolation of a replication-efficient mutant of West Nile virus from a persistently infected genetically resistant mouse cell culture. J Virol, 39: 413–421.

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Brinton M A. 2002. THE MOLECULAR BIOLOGY OF WEST NILE VIRUS: A New Invader of the Western Hemisphere. Annu Rev Microbiol, 56: 371–402.

    CAS  PubMed  Google Scholar 

  15. Burke D S, and Monath T P. 2001. Flaviviruses. Lippincott William & Wilkins.

    Google Scholar 

  16. CDC. 2010. CDC West Nile virus homepage. http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount03.htm.

    Google Scholar 

  17. Chambers T J, Grakoui A, and Rice C M. 1991. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J. Virol., 65: 6042–6050.

    CAS  PubMed Central  PubMed  Google Scholar 

  18. Chambers T J, Hahn C S, Galler R, and Rice C M. 1990. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol, 44: 649–688.

    CAS  PubMed  Google Scholar 

  19. Chambers T J, Nestorowicz A, Amberg S M, and Rice C M. 1993. Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication. J Virol, 67: 6797–6807.

    CAS  PubMed Central  PubMed  Google Scholar 

  20. Chambers T J, Droll D A, Tang Y, Liang Y, Ganesh V K, Murthy K H, and Nickells M. 2005. Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities. J Gen Virol, 86: 1403–1413.

    CAS  PubMed  Google Scholar 

  21. Chandramouli S, Joseph J S, Daudenarde S, Gatchalian J, Cornillez-Ty C, and Kuhn P. 2010. Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol, 84: 3059–3067.

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, and Katzenmeier G. 2005. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun, 330: 1237–1246.

    CAS  PubMed  Google Scholar 

  23. Chappell K J, Stoermer M J, Fairlie D P, and Young P R. 2006. Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J Biol Chem, 281: 38448–38458.

    CAS  PubMed  Google Scholar 

  24. Chappell K J, Stoermer M J, Fairlie D P, and Young P R. 2008. West Nile Virus NS2B/NS3 protease as an antiviral target. Curr Med Chem, 15: 2771–2784.

    CAS  PubMed  Google Scholar 

  25. Chappell K J, Stoermer M J, Fairlie D P, and Young P R. 2008. Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity. J Gen Virol, 89: 1010–1014.

    CAS  PubMed  Google Scholar 

  26. Cleaves G R, and Dubin D T. 1979. Methylation status of intracellular dengue type 2 40 S RNA. Virology, 96: 159–165.

    CAS  PubMed  Google Scholar 

  27. Cregar-Hernandez L, Jiao G S, Johnson A T, Lehrer A T, Wong T A, and Margosiak S A. 2011. Small molecule pan-dengue and West Nile virus NS3 protease inhibitors. Antivir Chem Chemother, 21: 209–217.

    CAS  PubMed Central  PubMed  Google Scholar 

  28. Daffis S, Szretter K J, Schriewer J, Li J, Youn S, Errett J, Lin T Y, Schneller S, Zust R, Dong H, Thiel V, Sen G C, Fensterl V, Klimstra W B, Pierson T C, Buller R M, Gale M, Jr., Shi P Y, and Diamond M S. 2010. 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature, 468: 452–456.

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Deng J, Li N, Liu H, Zuo Z, Liew O W, Xu W, Chen G, Tong X, Tang W, Zhu J, Zuo J, Jiang H, Yang C G, Li J, and Zhu W. 2012. Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping. J Med Chem, 55: 6278–6293.

    CAS  PubMed  Google Scholar 

  30. Dong H, Chang D C, Hua M H, Lim S P, Chionh Y H, Hia F, Lee Y H, Kukkaro P, Lok S M, Dedon P C, and Shi P Y. 2012. 2′-O methylation of internal adenosine by flavivirus NS5 methyltransferase. PLoS pathogens, 8: e1002642.

    CAS  PubMed Central  PubMed  Google Scholar 

  31. Egloff M P, Benarroch D, Selisko B, Romette J L, and Canard B. 2002. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. Embo J, 21: 2757–2768.

    CAS  PubMed  Google Scholar 

  32. Ekonomiuk D, Su X C, Ozawa K, Bodenreider C, Lim S P, Otting G, Huang D, and Caflisch A. 2009. Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. J Med Chem, 52: 4860–4868.

    CAS  PubMed  Google Scholar 

  33. Ekonomiuk D, Su X C, Ozawa K, Bodenreider C, Lim S P, Yin Z, Keller T H, Beer D, Patel V, Otting G, Caflisch A, and Huang D. 2009. Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. PLoS Negl Trop Dis, 3: e356.

    PubMed Central  PubMed  Google Scholar 

  34. Erbel P, Schiering N, D’Arcy A, Renatus M, Kroemer M, Lim S, Yin Z, Keller T, Vasudevan S, and Hommel U. 2006. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol., 13: 372–373.

    CAS  PubMed  Google Scholar 

  35. Ezgimen M, Lai H, Mueller N H, Lee K, Cuny G, Ostrov D A, and Padmanabhan R. 2012. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Antiviral Res, 94: 18–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  36. Falgout B, Miller R H, and Lai C J. 1993. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J Virol, 67: 2034–2042.

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Falgout B, Bray M, Schlesinger J J, and Lai C J. 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol, 64: 4356–4363.

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Falgout B, Pethel M, Zhang Y M, and Lai C J. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol, 65: 2467–2475.

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Ganesh V K, Muller N, Judge K, Luan C H, Padmanabhan R, and Murthy K H. 2005. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg Med Chem, 13: 257–264.

    CAS  PubMed  Google Scholar 

  40. Gao Y, Cui T, and Lam Y. 2010. Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease. Bioorg Med Chem, 18: 1331–1336.

    CAS  PubMed  Google Scholar 

  41. Gao Y, Samanta S, Cui T, and Lam Y. 2013. Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 1,3,4,5-Tetrasubstituted 1H-Pyrrol-2(5H)-one Scaffold. ChemMedChem, 8: 1554–1560.

    CAS  PubMed  Google Scholar 

  42. Gouvea I E, Izidoro M A, Judice W A, Cezari M H, Caliendo G, Santagada V, dos Santos C N, Queiroz M H, Juliano M A, Young P R, Fairlie D P, and Juliano L. 2007. Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates. Arch Biochem Biophys, 457: 187–196.

    CAS  PubMed  Google Scholar 

  43. Grant D, Tan G K, Qing M, Ng J K, Yip A, Zou G, Xie X, Yuan Z, Schreiber M J, Schul W, Shi P Y, and Alonso S. 2011. A Single Amino Acid in Nonstructural Protein NS4B Confers Virulence to Dengue Virus in AG129 Mice through Enhancement of Viral RNA Synthesis. J Virol, 85: 7775–7787.

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Guirakhoo F, Bolin R A, and Roehrig J T. 1992. The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein. Virology, 191: 921–931.

    CAS  PubMed  Google Scholar 

  45. Guo J, Hayashi J, and Seeger C. 2005. West nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol., 79: 1343–1350.

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Guyatt K J, Westaway E G, and Khromykh A A. 2001. Expression and purification of enzymatically active recombinant RNA-dependent RNA polymerase (NS5) of the flavivirus Kunjin. J Virol Methods, 92: 37–44.

    CAS  PubMed  Google Scholar 

  47. Hammamy M Z, Haase C, Hammami M, Hilgenfeld R, and Steinmetzer T. 2013. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem, 8: 231–241.

    CAS  PubMed  Google Scholar 

  48. Issur M, Geiss B J, Bougie I, Picard-Jean F, Despins S, Mayette J, Hobdey S E, and Bisaillon M. 2009. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. Rna, 15: 2340–2350.

    CAS  PubMed  Google Scholar 

  49. Jia F, Zou G, Fan J, and Yuan Z. 2010. Identification of palmatine as an inhibitor of West Nile virus. Arch Virol, 155: 1325–1329.

    CAS  PubMed  Google Scholar 

  50. Johnston P A, Phillips J, Shun T Y, Shinde S, Lazo J S, Huryn D M, Myers M C, Ratnikov B I, Smith J W, Su Y, Dahl R, Cosford N D, Shiryaev S A, and Strongin A Y. 2007. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol, 5: 737–750.

    CAS  PubMed  Google Scholar 

  51. Kiat T S, Pippen R, Yusof R, Ibrahim H, Khalid N, and Rahman N A. 2006. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett, 16: 3337–3340.

    CAS  PubMed  Google Scholar 

  52. Knehans T, Schuller A, Doan D N, Nacro K, Hill J, Guntert P, Madhusudhan M S, Weil T, and Vasudevan S G. 2011. Structure-guided fragment-based in silico drug design of dengue protease inhibitors. J Comput Aided Mol Des, 25: 263–274.

    CAS  PubMed  Google Scholar 

  53. Knox J E, Ma N L, Yin Z, Patel S J, Wang W L, Chan W L, Ranga Rao K R, Wang G, Ngew X, Patel V, Beer D, Lim S P, Vasudevan S G, and Keller T H. 2006. Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J Med Chem, 49: 6585–6590.

    CAS  PubMed  Google Scholar 

  54. Koonin E V. 1993. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J Gen Virol, 74: 733–740.

    CAS  PubMed  Google Scholar 

  55. Kramer L D, and Bernard K A. 2001. West Nile virus infection in birds and mammals. Ann N Y Acad Sci, 951: 84–93.

    CAS  PubMed  Google Scholar 

  56. Kramer L D, Li J, and Shi P Y. 2007. West Nile virus. Lancet Neurol, 6: 171–181.

    CAS  PubMed  Google Scholar 

  57. Kummerer B M, and Rice C M. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol., 76: 4773–4784.

    PubMed Central  PubMed  Google Scholar 

  58. Lai H, Sridhar Prasad G, and Padmanabhan R. 2013. Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro. Antiviral Res, 97: 74–80.

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Lai H, Dou D, Aravapalli S, Teramoto T, Lushington G H, Mwania T M, Alliston K R, Eichhorn D M, Padmanabhan R, and Groutas W C. 2013. Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases. Bioorg Med Chem, 21: 102–113.

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Leung D, Schroder K, White H, Fang N-X, Stoermer M, Abbenante G, Martin J, PR Y, and Fairlie D. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem., 276: 45762–45771.

    CAS  PubMed  Google Scholar 

  61. Leung J Y, Pijlman G P, Kondratieva N, Hyde J, Mackenzie J M, and Khromykh A A. 2008. Role of nonstructural protein NS2A in flavivirus assembly. J Virol, 82: 4731–4741.

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Li H, Clum S, You S, Ebner K E, and Padmanabhan R. 1999. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J Virol, 73: 3108–3116.

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Li J, Lim S P, Beer D, Patel V, Wen D, Tumanut C, Tully D C, Williams J A, Jiricek J, Priestle J P, Harris J L, and Vasudevan S G. 2005. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem, 280: 28766–28774.

    CAS  PubMed  Google Scholar 

  64. Li L, Lok S M, Yu I M, Zhang Y, Kuhn R J, Chen J, and Rossmann M G. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science, 319: 1830–1834.

    CAS  PubMed  Google Scholar 

  65. Lin C, Kwong A D, and Perni R B. 2006. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets, 6: 3–16.

    CAS  PubMed  Google Scholar 

  66. Lin K, Perni R B, Kwong A D, and Lin C. 2006. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother, 50: 1813–1822.

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Lindenbach B D, and Rice C M. 1997. trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J. Virol., 71: 9608–9617.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Lindenbach B D, and Rice C M. 1999. Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function. J Virol, 73: 4611–4621.

    CAS  PubMed Central  PubMed  Google Scholar 

  69. Lindenbach B D, Thiel H J, and Rice C M. 2007. Flaviviridae: The Virus and Their Replication, Fourth ed. Lippincott William & Wilkins.

    Google Scholar 

  70. Luo D, Xu T, Hunke C, Gruber G, Vasudevan S G, and Lescar J. 2008. Crystal structure of the NS3 protease-helicase from dengue virus. J Virol, 82: 173–183.

    CAS  PubMed Central  PubMed  Google Scholar 

  71. Luo D, Wei N, Doan D N, Paradkar P N, Chong Y, Davidson A D, Kotaka M, Lescar J, and Vasudevan S G. 2010. Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J Biol Chem, 285: 18817–18827.

    CAS  PubMed  Google Scholar 

  72. Luo D, Xu T, Watson R P, Scherer-Becker D, Sampath A, Jahnke W, Yeong S S, Wang C H, Lim S P, Strongin A, Vasudevan S G, and Lescar J. 2008. Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein. Embo J, 27: 3209–3219.

    CAS  PubMed  Google Scholar 

  73. Mangano D T, Tudor I C, and Dietzel C. 2006. The risk associated with aprotinin in cardiac surgery. N Engl J Med, 354: 353–365.

    CAS  PubMed  Google Scholar 

  74. Mangano D T, Miao Y, Vuylsteke A, Tudor I C, Juneja R, Filipescu D, Hoeft A, Fontes M L, Hillel Z, Ott E, Titov T, Dietzel C, and Levin J. 2007. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA, 297: 471–479.

    CAS  PubMed  Google Scholar 

  75. Marianneau P, Steffan A M, Royer C, Drouet M T, Jaeck D, Kirn A, and Deubel V. 1999. Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol, 73: 5201–5206.

    CAS  PubMed Central  PubMed  Google Scholar 

  76. Menendez-Arias L. 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res, 85: 210–231.

    CAS  PubMed  Google Scholar 

  77. Miller S, Kastner S, Krijnse-Locker J, Buhler S, and Bartenschlager R. 2007. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J Biol Chem, 282: 8873–8882.

    CAS  PubMed  Google Scholar 

  78. Modis Y, Ogata S, Clements D, and Harrison S C. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature, 427: 313–319.

    CAS  PubMed  Google Scholar 

  79. Mueller N H, Yon C, Ganesh V K, and Padmanabhan R. 2007. Characterization of the West Nile virus protease substrate specificity and inhibitors. Int J Biochem Cell Biol, 39: 606–614.

    CAS  PubMed  Google Scholar 

  80. Mueller N H, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson T C, and Padmanabhan R. 2008. Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother, 52: 3385–3393.

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Munoz-Jordan J L, Sanchez-Burgos G G, Laurent-Rolle M, and Garcia-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA, 100: 14333–14338.

    CAS  PubMed  Google Scholar 

  82. Munoz-Jordan J L, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin W I, and Garcia-Sastre A. 2005. Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses. J. Virol., 79: 8004–8013.

    CAS  PubMed Central  PubMed  Google Scholar 

  83. Muylaert I R, Galler R, and Rice C M. 1997. Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J. Virol., 71: 291–298.

    CAS  PubMed Central  PubMed  Google Scholar 

  84. Nall T A, Chappell K J, Stoermer M J, Fang N X, Tyndall J D, Young P R, and Fairlie D P. 2004. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem, 279: 48535–48542.

    CAS  PubMed  Google Scholar 

  85. Nitsche C, Steuer C, and Klein C D. 2011. Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases. Bioorg Med Chem, 19: 7318–7337.

    CAS  PubMed  Google Scholar 

  86. Nitsche C, Behnam M A, Steuer C, and Klein C D. 2012. Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. Antiviral Res, 94: 72–79.

    CAS  PubMed  Google Scholar 

  87. Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C, Panyim S, and Katzenmeier G. 2004. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J Virol, 78: 13708–13716.

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Noble C G, Seh C C, Chao A T, and Shi P Y. 2012. Ligand-bound structures of the dengue virus protease reveal the active conformation. Journal of Virology, 86: 438–446.

    CAS  PubMed Central  PubMed  Google Scholar 

  89. Noble C G, Chen Y L, Dong H, Gu F, Lim S P, Schul W, Wang Q Y, and Shi P Y. 2010. Strategies for development of Dengue virus inhibitors. Antiviral Res, 85: 450–462.

    CAS  PubMed  Google Scholar 

  90. Pambudi S, Kawashita N, Phanthanawiboon S, Omokoko M D, Masrinoul P, Yamashita A, Limkittikul K, Yasunaga T, Takagi T, Ikuta K, and Kurosu T. 2013. A Small Compound Targeting the Interaction between Nonstructural Proteins 2B and 3 Inhibits Dengue Virus Replication. Biochem Biophys Res Commun: in press (doi: 10.1016/j.bbrc.2013.1009.1078).

    Google Scholar 

  91. Phong W Y, Moreland N J, Lim S P, Wen D, Paradkar P N, and Vasudevan S G. 2011. Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target. Bioscience reports.

    Google Scholar 

  92. Radichev I, Shiryaev S A, Aleshin A E, Ratnikov B I, Smith J W, Liddington R C, and Strongin A Y. 2008. Structure-based mutagenesis identifies important novel determinants of the NS2B cofactor of the West Nile virus two-component NS2B-NS3 proteinase. J Gen Virol, 89: 636–641.

    CAS  PubMed  Google Scholar 

  93. Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, Dong H, Deas T, Zhou Y, Li H, and Shi P. 2006. West nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5. J. Virol., 80: 8362–8370.

    CAS  PubMed Central  PubMed  Google Scholar 

  94. Rice C M, Lenches E M, Eddy S R, Shin S J, Sheets R L, and Strauss J H. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science, 229: 726–733.

    CAS  PubMed  Google Scholar 

  95. Robin G, Chappell K, Stoermer M J, Hu S H, Young P R, Fairlie D P, and Martin J L. 2009. Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol, 385: 1568–1577.

    CAS  PubMed  Google Scholar 

  96. Romano K P, Ali A, Royer W E, and Schiffer C A. 2010. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A, 107: 20986–20991.

    CAS  PubMed Central  PubMed  Google Scholar 

  97. Roosendaal J, Westaway E G, Khromykh A, and Mackenzie J M. 2006. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J Virol, 80: 4623–4632.

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Rothan H A, Han H C, Ramasamy T S, Othman S, Rahman N A, and Yusof R. 2012. Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect Dis, 12: 314.

    CAS  PubMed Central  PubMed  Google Scholar 

  99. Samanta S, Cui T, and Lam Y. 2012. Discovery, synthesis, and in vitro evaluation of West Nile virus protease inhibitors based on the 9,10-dihydro-3H,4aH-1,3,9,10a-tetraazaphenanthren-4-one scaffold. ChemMedChem, 7: 1210–1216.

    CAS  PubMed  Google Scholar 

  100. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta S K, Hussain M, Shah A, Cutler D, Zhang J, and Zeuzem S. 2007. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology, 132: 1270–1278.

    CAS  PubMed  Google Scholar 

  101. Schuller A, Yin Z, Brian Chia C S, Doan D N, Kim H K, Shang L, Loh T P, Hill J, and Vasudevan S G. 2011. Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease. Antiviral Res, 92: 96–101.

    PubMed  Google Scholar 

  102. Shi P Y, Tilgner M, and Lo M K. 2002. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology, 296: 219–233.

    CAS  PubMed  Google Scholar 

  103. Shi P Y, Tilgner M, Lo M K, Kent K A, and Bernard K A. 2002. Infectious cDNA clone of the epidemic west nile virus from New York City. J Virol, 76: 5847–5856.

    CAS  PubMed Central  PubMed  Google Scholar 

  104. Shi P Y, Kauffman E B, Ren P, Felton A, Tai J H, Dupuis A P, 2nd, Jones S A, Ngo K A, Nicholas D C, Maffei J, Ebel G D, Bernard K A, and Kramer L D. 2001. High-throughput detection of West Nile virus RNA. J Clin Microbiol, 39: 1264–1271.

    CAS  PubMed Central  PubMed  Google Scholar 

  105. Shiryaev S, Ratnikov B, Chekanov A, Sikora S, Rozanov D, Godzik A, Wang J, Smith J, Huang Z, Lindberg I, Samuel M, Diamond M, and Strongin A. 2006. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J., 393: 503–511.

    CAS  PubMed  Google Scholar 

  106. Sidique S, Shiryaev S A, Ratnikov B I, Herath A, Su Y, Strongin A Y, and Cosford N D. 2009. Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase. Bioorg Med Chem Lett, 19: 5773–5777.

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Steuer C, Gege C, Fischl W, Heinonen K H, Bartenschlager R, and Klein C D. 2011. Synthesis and biological evaluation of alpha-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. Bioorg Med Chem, 19: 4067–4074.

    CAS  PubMed  Google Scholar 

  108. Stoermer M J, Chappell K J, Liebscher S, Jensen C M, Gan C H, Gupta P K, Xu W J, Young P R, and Fairlie D P. 2008. Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem, 51: 5714–5721.

    CAS  PubMed  Google Scholar 

  109. Tan B H, Fu J, Sugrue R J, Yap E H, Chan Y C, and Tan Y H. 1996. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology, 216: 317–325.

    CAS  PubMed  Google Scholar 

  110. Tassaneetrithep B, Burgess T H, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller M A, Pattanapanyasat K, Sarasombath S, Birx D L, Steinman R M, Schlesinger S, and Marovich M A. 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med, 197: 823–829.

    CAS  PubMed Central  PubMed  Google Scholar 

  111. Tiew K C, Dou D, Teramoto T, Lai H, Alliston K R, Lushington G H, Padmanabhan R, and Groutas W C. 2012. Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives. Bioorg Med Chem, 20: 1213–1221.

    CAS  PubMed Central  PubMed  Google Scholar 

  112. Tomlinson S M, and Watowich S J. 2011. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease. Antiviral Res, 89: 127–135.

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Tomlinson S M, and Watowich S J. 2012. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors. Antiviral Res, 93: 245–252.

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Tomlinson S M, Malmstrom R D, Russo A, Mueller N, Pang Y P, and Watowich S J. 2009. Structure-based discovery of dengue virus protease inhibitors. Antiviral Res, 82: 110–114.

    CAS  PubMed Central  PubMed  Google Scholar 

  115. Umareddy I, Chao A, Sampath A, Gu F, and Vasudevan S G. 2006. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J Gen Virol, 87: 2605–2614.

    CAS  PubMed  Google Scholar 

  116. USGS. 2010. Disease Maps 2010. http://diseasemaps.usgs.gov/.

    Google Scholar 

  117. Warrener P, Tamura J K, and Collett M S. 1993. RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. J Virol, 67: 989–996.

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Wegzyn C M, and Wyles D L. 2012. Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV). Curr Opin Pharmacol, 12: 556–561.

    CAS  PubMed  Google Scholar 

  119. Wengler G. 1981. Terminal sequences of the genome and replicative-from RNA of the flavivirus West Nile virus: absence of poly(A) and possible role in RNA replication. Virology, 113: 544–555.

    CAS  PubMed  Google Scholar 

  120. Wengler G. 1991. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology, 184: 707–715.

    CAS  PubMed  Google Scholar 

  121. Westaway E G, Brinton M A, Gaidamovich S Y, Horzinek M C, Igarashi A, Kaariainen L, Lvov D K, Porterfield J S, Russell P K, and Trent D W. 1985. Flaviviridae. Intervirol., 24: 183–192.

    CAS  Google Scholar 

  122. WHO. 2009. Immunization, vaccines and biologicals: Japanese encephalitis. 〈http://www.who.int/nuvi/je/en/〉.

    Google Scholar 

  123. WHO. 2009. Dengue factsheet. 〈http://www.who.int/mediacentre/factsheets/fs117/en/〉.

    Google Scholar 

  124. WHO. 2009. Yellow fever factsheet. 〈http://www.who.int/mediacentre/factsheets/fs100/en/〉.

    Google Scholar 

  125. Wyles D L. 2012. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med, 20: 139–145.

    PubMed  Google Scholar 

  126. Wyles D L. 2013. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis, 207Suppl 1: S33–39.

    CAS  PubMed  Google Scholar 

  127. Xu S, Li H, Shao X, Fan C, Ericksen B, Liu J, Chi C, and Wang C. 2012. Critical effect of peptide cyclization on the potency of peptide inhibitors against Dengue virus NS2B-NS3 protease. J Med Chem, 55: 6881–6887.

    CAS  PubMed  Google Scholar 

  128. Yang C C, Hsieh Y C, Lee S J, Wu S H, Liao C L, Tsao C H, Chao Y S, Chern J H, Wu C P, and Yueh A. 2011. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob Agents Chemother, 55: 229–238.

    CAS  PubMed Central  PubMed  Google Scholar 

  129. Yin Z, Patel S J, Wang W L, Wang G, Chan W L, Rao K R, Alam J, Jeyaraj D A, Ngew X, Patel V, Beer D, Lim S P, Vasudevan S G, and Keller T H. 2006. Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead. Bioorg Med Chem Lett, 16: 36–39.

    CAS  PubMed  Google Scholar 

  130. Yin Z, Patel S J, Wang W L, Chan W L, Ranga Rao K R, Wang G, Ngew X, Patel V, Beer D, Knox J E, Ma N L, Ehrhardt C, Lim S P, Vasudevan S G, and Keller T H. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett, 16: 40–43.

    CAS  PubMed  Google Scholar 

  131. Zhang Y, Corver J, Chipman P R, Zhang W, Pletnev S V, Sedlak D, Baker T S, Strauss J H, Kuhn R J, and Rossmann M G. 2003. Structures of immature flavivirus particles. EMBO J., 22: 2604–2613.

    CAS  PubMed  Google Scholar 

  132. Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, Guo Y, Bernard K A, Shi P Y, and Li H. 2007. Structure and function of flavivirus NS5 methyltransferase. J Virol, 81: 3891–3903.

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hongmin Li.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Brecher, M., Zhang, J. & Li, H. The flavivirus protease as a target for drug discovery. Virol. Sin. 28, 326–336 (2013). https://doi.org/10.1007/s12250-013-3390-x

Download citation

Keywords

  • Flavivirus
  • Inhibitor
  • Protease